Mitigating hERG Inhibition: Design of Orally Bioavailable CCR5 Antagonists as Potent Inhibitors of R5 HIV-1 Replication

被引：9

作者：

Skerlj, Renato ^{[1
]}

Bridger, Gary ^{[2
]}

Zhou, Yuanxi ^{[2
]}

Bourque, Elyse ^{[1
]}

McEachern, Ernest ^{[2
]}

Danthi, Sanjay ^{[1
]}

Langille, Jonathan ^{[2
]}

Harwig, Curtis ^{[2
]}

Veale, Duane ^{[2
]}

Carpenter, Bryon ^{[2
]}

Ba, Tuya ^{[2
]}

Bey, Michael ^{[2
]}

Baird, Ian ^{[2
]}

Wilson, Trevor ^{[2
]}

Metz, Markus ^{[1
]}

MacFarland, Ron ^{[2
]}

Mosi, Renee ^{[2
]}

Bodart, Veronique ^{[2
]}

Wong, Rebecca ^{[2
]}

Fricker, Simon ^{[1
]}

Huskens, Dana ^{[3
]}

Schols, Dominique ^{[3
]}

机构：

[1] Genzyme Corp, Waltham, MA 02451 USA

[2] Anormed Inc, Langley, BC V2Y 1N5, Canada

[3] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2012年 / 3卷 / 03期

基金：

英国医学研究理事会;

关键词：

HIV-1; hERG; CCR5; chemokine receptor; LONG-QT SYNDROME; MARAVIROC; GO;

D O I：

10.1021/ml2002604

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A series of CCR5 antagonists representing the thiophene-3-yl-methyl ureas were designed that met the pharmacological criteria for HIV-1 inhibition and mitigated a human ether-a-go-go related gene (hERG) inhibition liability. Reducing lipophilicity was the main design criteria used to identify compounds that did not inhibit the hERG channel, but subtle structural modifications were also important. Interestingly, within this series, compounds with low hERG inhibition prolonged the action potential duration (APD) in dog Purkinje fibers, suggesting a mixed effect on cardiac ion channels.

引用

页码：216 / 221

页数：6

共 50 条

[1] Design and synthesis of pyridin-2-yloxymethylpiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication
Skerlj, Renato
Bridger, Gary
Zhou, Yuanxi
Bourque, Elyse
Langille, Jonathan
Di Fluri, Maria
Bogucki, David
Yang, Wen
Li, Tongshuang
Wang, Letian
Nan, Susan
Baird, Ian
Metz, Markus
Darkes, Marilyn
Labrecque, Jean
Lau, Gloria
Fricker, Simon
Huskens, Dana
Schols, Dominique
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (08) : 2450 - 2455
[2] Design and synthesis of pyridin-2-ylmethylaminopiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication
Skerlj, Renato
Bridger, Gary
Zhou, Yuanxi
Bourque, Elyse
McEachern, Ernest
Langille, Jonathan
Harwig, Curtis
Veale, Duane
Yang, Wen
Li, Tongshong
Zhu, Yongbao
Bey, Michael
Baird, Ian
Sartori, Michael
Metz, Markus
Mosi, Renee
Nelson, Kim
Bodart, Veronique
Wong, Rebecca
Fricker, Simon
Mac Farland, Ron
Huskens, Dana
Schols, Dominique
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (23) : 6950 - 6954
[3] Design of Substituted lmidazolidinylpiperidinylbenzoic Acids as Chemokine Receptor 5 Antagonists: Potent Inhibitors of R5 HIV-1 Replication
Skerlj, Renato
Bridge, Gary
Zhou, Yuanxi
Bourque, Elyse
McEachern, Ernest
Metz, Markus
Harwig, Curtis
Li, Tong-Shuang
Yang, Wen
Bogucki, David
Zhu, Yongbao
Langille, Jonathan
Veale, Duane
Ba, Tuya
Bey, Michael
Baird, Ian
Kaller, Alan
Krumpak, Maria
Leitch, David
Satori, Michael
Vocadlo, Krystyna
Guay, Danielle
Nan, Susan
Yee, Helen
Crawford, Jason
Chen, Gang
Wilson, Trevor
Carpenter, Bryon
Gauthier, David
MacFarland, Ron
Mosi, Renee
Bodart, Veronique
Wong, Rebecca
Fricker, Simon
Schols, Dominique
JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (20) : 8049 - 8065
[4] CCR5 inhibitors in HIV-1 therapy
Dorr, Patrick
Perros, Manos
EXPERT OPINION ON DRUG DISCOVERY, 2008, 3 (11) : 1345 - 1361
[5] The promise of CCR5 antagonists as new therapies for HIV-1
Repik, Alexander
Richards, Kathryn H.
Clapham, Paul R.
CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2007, 8 (02) : 130 - 139
[6] The EBI2 receptor is coexpressed with CCR5 in CD4+ T cells and boosts HIV-1 R5 replication
Guigues, Adeline
Gimenez, Sandrine
Mettling, Clement
Maurel, Damien
Doumazane, Etienne
Prezeau, Laurent
Francois, Vincent
Corbeau, Pierre
AIDS, 2024, 38 (10) : 1449 - 1459
[7] Preferential recognition of monomeric CCR5 expressed in cultured cells by the HIV-1 envelope glycoprotein gp120 for the entry of R5 HIV-1
Nakano, Yusuke
Monde, Kazuaki
Terasawa, Hiromi
Yuan, Yuzhe
Yusa, Keisuke
Harada, Shinji
Maeda, Yosuke
VIROLOGY, 2014, 452 : 117 - 124
[8] CCR5 antagonists and HIV-1 infection: Bases and consequences of this therapeutic approach
Psomas, K. C.
Corbeau, P.
Reynes, J.
ANTIBIOTIQUES, 2010, 12 (01): : 27 - 41
[9] Discovery of INCB9471, a Potent, Selective, and Orally Bioavailable CCR5 Antagonist with Potent Anti-HIV-1 Activity
Xue, Chu-Biao
Chen, Lihua
Cao, Ganfeng
Zhang, Ke
Wang, Anlai
Meloni, David
Glenn, Joseph
Anand, Rajan
Xia, Michael
Kong, Ling
Huang, Taisheng
Feng, Hao
Zheng, Changsheng
Li, Mei
Galya, Laurine
Zhou, Jiacheng
Shin, Niu
Baribaud, Fredric
Solomon, Kim
Scherle, Peggy
Zhao, Bitao
Diamond, Sharon
Emm, Tom
Keller, Douglas
Contel, Nancy
Yeleswaram, Swamy
Vaddi, Kris
Hollis, Gregory
Newton, Robert
Friedman, Steven
Metcalf, Brian
ACS MEDICINAL CHEMISTRY LETTERS, 2010, 1 (09): : 483 - 487
[10] Interaction of small molecule inhibitors of HIV-1 entry with CCR5
Seibert, Christoph
Ying, Weiwen
Gavrilov, Svetlana
Tsamis, Fotini
Kuhmann, Shawn E.
Palani, Anandan
Tagat, Jayaram R.
Clader, John W.
McCombie, Stuart W.
Baroudy, Bahige M.
Smith, Steven O.
Dragic, Tatjana
Moore, John P.
Sakmar, Thomas P.
VIROLOGY, 2006, 349 (01) : 41 - 54

← 1 2 3 4 5 →